Sex: M
Vaccine: TYP
Symptoms: COVID-19, Incomplete course of vaccination, SARS-CoV-2 test
Clinical narrative: COVID; Stopped taking typhoid capsules; Took 2 capsules with food; A spontaneous report was received from a male patient of unknown age on 28AUG2023 who had "COVID" (PT: COVID-19) due to which the patient "stopped taking typhoid capsules" (PT: Incomplete course of vaccination) and after restarting the Vivotif course "took 2 capsules with food" (PT: Product administration error). The patient took oral Vivotif capsules (typhoid vaccine live oral Ty21A; lot number: unknown) as a prophylactic vaccination against typhoid.  The patient's medical history, concomitant medications, or allergies were not reported.  On an unknown date in 2023, three weeks ago, the patient started a course of Vivotif, but meanwhile, he got coronavirus disease (COVID). Therefore, the patient stopped taking the typhoid capsules and took "Pavlomax" as a treatment medication. It was reported that the patient had a severe migraine for 30 hours, which was referred to as moderate COVID.  After testing negative for COVID, the patient restarted the Vivotif vaccination course and was given four capsules to complete the entire course. Reportedly, the patient took two capsules of Vivotif with food.  The patient recovered from the event "COVID" on an unknown date in 2023 while the outcome of the events "stopped taking typhoid capsules" and "took 2 capsules with food" was not applicable.  The action taken with Vivotif with respect to the events "stopped taking typhoid capsules" and "took 2 capsules with food" was not applicable and for event "COVID" it was withdrawn.  No additional information was reported.  Company comment: It was reported that a patient started the course of Vivotif, but meanwhile, he got coronavirus disease (COVID-19) due to which the patient stopped taking the typhoid capsules (incomplete course of vaccination). After testing negative for COVID, the patient restarted the Vivotif but he took two capsules with food (product administration error). COVID-19 is a highly communicable disease affecting a large number of people worldwide, however, as the event occurred while the patient was on Vivotif, it's role cannot be completely ruled out and the causality assessment of COVID-19 is conservatively considered possible with Vivotif. Furthermore, due to the nature of the events, the causality of incomplete course of vaccination and product administration error is not applicable with Vivotif. The case is considered non serious as per medical assessment. Limited information precludes further assessment.  On 08SEP2023, follow-up information was received from the patient.  It was reported that the patient took two doses of Vivotif before COVID infection and restarted Vivotif around two weeks (date unspecified) after the recovery from COVID. Reportedly, the patient administered all the four doses of Vivotif after recovering from COVID infection.  Company comment: It was reported that a patient started the course of Vivotif, but meanwhile, he got coronavirus disease (COVID-19) due to which the patient stopped taking the typhoid capsules (incomplete course of vaccination). After testing negative for COVID, the patient restarted the Vivotif but he took two capsules with food (product administration error). COVID-19 is a highly communicable disease affecting a large number of people worldwide, however, as the event occurred while the patient was on Vivotif, it's role cannot be completely ruled out and the causality assessment of COVID-19 is conservatively considered possible with Vivotif. Furthermore, due to the nature of the events, the causality of incomplete course of vaccination and product administration error is not applicable with Vivotif. The case is considered non serious as per medical assessment. Limited information precludes further assessment.; Sender's Comments: It was reported that a patient started the course of Vivotif, but meanwhile, he got coronavirus disease (COVID-19) due to which the patient stopped taking the typhoid capsules (incomplete course of vaccination). After testing negative for COVID, the patient restarted the Vivotif but he took two capsules with food (product administration error). COVID-19 is a highly communicable disease affecting a large number of people worldwide, however, as the event occurred while the patient was on Vivotif, it's role cannot be completely ruled out and the causality assessment of COVID-19 is conservatively considered possible with Vivotif. Furthermore, due to the nature of the events, the causality of incomplete course of vaccination and product administration error is not applicable with Vivotif. The case is considered non serious as per medical assessment. Limited information precludes further assessment.